GlassScriptPhysician profile
Mary Parker
NPI 1568773273
$7,146.49
in general payments reported to CMS, 2019-2025
32 companies · $1,254 in 2025
The $1,254 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $384 · 2021: $683 · 2022: $1,071 · 2023: $1,456 · 2024: $1,669 · 2025: $1,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,217 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,217.20 |
| Education | $160.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,155.10 | 2019-2025 | |
| Janssen Biotech, INC. | $897.99 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $709.30 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $566.68 | 2020-2025 | Dupixent, Libtayo |
| Pfizer INC. | $389.21 | 2019-2025 | |
| Genzyme Corporation | $369.47 | 2019-2025 | |
| Incyte Corporation | $338.90 | 2021-2025 | Opzelura |
| Amgen INC. | $309.76 | 2020-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $281.47 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $279.71 | 2019-2025 | Adbry |
| Galderma Laboratories, L.P. | $256.22 | 2019-2025 | Aklief, Oracea, Twyneo |
| Almirall LLC | $231.32 | 2019-2024 | Seysara |
| Arcutis Biotherapeutics, INC. | $231.01 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $205.82 | 2020-2025 | Absorica Ld, Winlevi |
| Dermavant Sciences, INC. | $113.36 | 2022-2024 | Vtama |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $99.64 | 2024-2025 | Bimzelx |
| Angiodynamics, INC. | $95.64 | 2022 | |
| Lilly USA, LLC | $94.43 | 2019-2024 | Taltz, Olumiant |
| Epi Health, LLC | $85.22 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $78.29 | 2019-2023 | Jublia |
| Medimetriks Pharmaceuticals, INC. | $63.46 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $44.16 | 2019-2021 | |
| Botanix Sb INC | $26.03 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $21.72 | 2024 | Ycanth |
| Allergan, INC. | $21.63 | 2021 | |
| Aclaris Therapeutics, INC. | $19.46 | 2019 | |
| Celgene Corporation | $18.19 | 2019 | |
| Lnhc, INC | $17.32 | 2025 | Zelsuvmi |
| Journey Medical Corporation | $16.60 | 2020 | |
| Biofrontera INC. | $16.52 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Dermira, INC. | $12.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.